SAFETY AND EFFICACY OF A MICRONEEDLING DEVICE USED IN FACIAL AESTHETICS

NCT ID: NCT06933225

Last Updated: 2025-06-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-09-01
• Study Completion Date: 2026-02-28

Brief Summary

Microneedling (MN), also referred to as collagen induction therapy, uses small needles to create mechanical injury to the skin. The basis of MN relies on physical trauma. It has been proposed that the trauma generated by needle penetration in the skin induces regeneration of the dermis The needles penetrate the stratum corneum and create small holes known as micro-conduits with minimal damage to the epidermis.

MN therapy is widely used to improve the appearance of facial scars, stretch marks and rejuvenate photoaged skin. Recently, it has been shown that MN can improve skin wrinkles on the face. MN can be used alone or to increase absorption of topical medications, growth factors, or deliver radiofrequency directly to the dermis.

The product tested is a microneedling device with 20 micro-needles of 1.00 mm depth penetration. This microneedling device is considered as a medical device in the US but not in Europe, according to Appendix XVI of the European regulation on medical devices 2017/745 of 5 April 2017. It is not yet commercialized neither in Europe nor in US. This first-in-man, pilot, clinical study is designed to first confirm the cutaneous tolerance of the device and provide some first data on device performance. For this purpose, 33 subjects with mild to moderate wrinkles on the face and seeking improvement of his/her face aspect, will be treated on Day 0 and Day 30 with the microneedling device on the face. Follow-up visits will be done 30 and 60 days after first treatment. Treatment Site Reactions (TSR) and Adverse reactions (ARs) will be collected to evaluate the device safety. Change from baseline of wrinkle severity and Global Aesthetic Improvement Scale (GAIS) will be used to evaluate product performance. Subject evaluation will also be analysed, and photos will be taken to illustrate device effect.

Conditions

Skin Aging

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WOW fusion Microneedling Device, 1.00 mm

One treatment session on the whole face, on D0 and second treatment on D30.

Group Type: EXPERIMENTAL

WOW fusion Microneedling Device, 1.00 mm

Intervention Type: OTHER

One treatment session on the whole face, on D0 and second treatment on D30.

Interventions

WOW fusion Microneedling Device, 1.00 mm

One treatment session on the whole face, on D0 and second treatment on D30.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Healthy subject.

2. Sex: male and female

3. Age: 18 years or older

4. Subject seeking an improvement of her/his face aspect using an aesthetic procedure.

5. Subject with mild to moderate wrinkles (grade 1, 2 or 3 on the 6-points Lemperle Scales) on at least 2 of the following area:

• Horizontal forehead lines
• Periorbital lines
• Cheek folds

6. Subject willing to abstain from other facial aesthetic procedure in the full face through the entire study duration.

7. Subject having given their free, express, and informed consent.

8. Subject psychologically able to understand the information related to the study, and to give their written informed consent.

9. Subject registered with a social security scheme.

10. Female of childbearing potential must use a medically accepted contraceptive method since at least 12 weeks before the beginning of the study and throughout the study.

11. Female subjects of childbearing potential must have a negative pregnancy test at the inclusion.

Exclusion Criteria

• 1. Subjects who are pregnant, nursing or intend to become pregnant during study participation.

2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.

3. Subject in a social or sanitary establishment. 4. Subjects that are currently enrolled in another drug or device study. 5. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).

6. Subjects with a history of allergies or hypersensitivity to any components or ingredients in the device (especially allergy to nickel or gold).

7. Subjects with severe allergies manifested by a history of anaphylaxis, or history or presence of multiple and severe allergies.

8. Subjects that have any skin pathology or condition including tattooing or scarring that could interfere with the evaluation of the treatment areas.

9. Subjects who suffer from rosacea, eczema, psoriasis, atopic dermatitis, sun-burned or broken skin, inflammatory or irritated skin conditions, active cold sores, moderate to severe acne, abscess, herpes, unhealed wound, cancerous or precancerous lesion on the face.or are taking any prescribed medication for their skin or any skin disease.

10. Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk.

11. Subject with known history of or suffering from autoimmune disease and/or immune deficiency.

12. Subject predisposed to keloids or hypertrophic scarring. 13. Subjects who have a hemorrhagic (bleeding) disorder or hemostatic (bleeding) dysfunction.

14. Subject with pigmentation disorders (vitiligo, melasma,….). 15. Subjects who have had any form of collagen soft tissue treatment within the last 12 months.

16. Subject having resorbable filling product (e.g., hyaluronic acid) injections, an ultrasound-based treatment, a dermabrasion, a deep chemical peeling or other ablative procedure on the face within the past 12 months prior to study start and a facial surgery in the past 2 years.

17. Subject having received injections of permanent (e.g., acrylate polymers, silicone, polytetrafluoroethylene) or semi-permanent filling on the face (L Polylactic acid, Calcium Hydroxyapatite...).

18. Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand).

19. Subjects having received botulinum toxin in the face within the 9 previous months.

20. Subject having received mesotherapy products in the face within the 6 previous months.

21. Subject having done a superficial or medium peeling or a superficial scrub on the face or having received LED or laser treatment on the face within the 2 previous months.

22. Subject having used cosmetic products with alpha hydroxy acids (AHA) in the previous month.

23. Subjects who are currently, or within the past 3 months, treated with any systemic immunosuppressive therapy including but not limited to chemotherapy agents or corticosteroids (including inhaled or insufflated corticosteroids).

24. Subjects who are currently, or within the past 3 months, treated with any topical OTC drug or prescription therapy on their face.

25. Subjects taking an antithrombotic, antiplatelet or other blood thinning medications in the past 3 months.

26. Subject taking food supplement with an effect on skin quality (collagen, DHEA, …) in the 3 previous months.

27. Subjects that have received an investigational drug or device within 30 days prior to entering this study.

28. Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Circa Skin Ltd

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Eurofins Dermscan Pharmascan

Villeurbanne, , France

Countries

France

Central Contacts

Krystell M QARA Manager

Role: CONTACT

krystell@circaskin.co.uk

07429164205

Facility Contacts

Manon M Clinical Project Manager

Role: primary

manon.laune@cpt.eurofinseu.com

+ 33 472 823 656

Other Identifiers

2024-A01913-44

Identifier Type: OTHER

Identifier Source: secondary_id

22E1008

Identifier Type: -

Identifier Source: org_study_id